TY - JOUR
T1 - Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD
T2 - The Chronic Renal Insufficiency Cohort (CRIC) Study
AU - CRIC Study Investigators
AU - Bansal, Nisha
AU - Zelnick, Leila R.
AU - Soliman, Elsayed Z.
AU - Anderson, Amanda
AU - Christenson, Robert
AU - DeFilippi, Christopher
AU - Deo, Rajat
AU - Feldman, Harold I.
AU - He, Jiang
AU - Ky, Bonnie
AU - Kusek, John
AU - Lash, James
AU - Seliger, Stephen
AU - Shafi, Tariq
AU - Wolf, Myles
AU - Go, Alan S.
AU - Shlipak, Michael G.
AU - Appel, Lawrence J.
AU - Rao, Panduranga S.
AU - Rahman, Mahboob
AU - Townsend, Raymond R.
N1 - Funding Information:
Lawrence J. Appel, MD, MPH, Panduranga S. Rao, MD, Mahboob Rahman, MD, Raymond R. Townsend, MD. Nisha Bansal, MD, Leila R. Zelnick, PhD, Elsayed Soliman, MD, Amanda Anderson, PhD, Robert Christenson, PhD, Christopher DeFilippi, MD, Rajat Deo, MD, Harold I. Feldman, MD, Jiang He, MD, PhD, Bonnie Ky, MD, John Kusek, PhD, James Lash, MD, Stephen Seliger, MD, Tariq Shafi, MD, Myles Wolf, MD, Alan S. Go, MD, and Michael G. Shlipak, MD. Research idea and study design: NB, MGS; data acquisition: NB, AA, RC, HIF, JH, JK, JL, ASG, MGS; data analysis and interpretation: NB, LRZ, EZS, AA, RC, CD, RD, HIF, JH, BK, JK, JL, SS, TS, MW, ASG, MGS; statistical analysis: LRZ; supervision or mentorship: NB, MGS. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate. This study was supported by NIH grants R01 DK103612 (NB) and R01 DK104730 (AA). Roche Diagnostics provided partial funding for the NT-proBNP and hsTnT assays. Funding for the CRIC Study was obtained under a cooperative agreement from National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902). In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (NCATS) UL1TR000003, Johns Hopkins University UL1 TR-000424, University of Maryland General Clinical Research Center M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the NCATS component of NIH and NIH roadmap for Medical Research, Michigan Institute for Clinical and Health Research UL1TR000433, University of Illinois at Chicago Clinical and Translational Science Award UL1RR029879, Tulane Center of Biomedical Research Excellence for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036, Kaiser Permanente NIH/National Center for Research Resources UCSF-CTSI UL1 RR-024131, and an unrestricted fund from the Northwest Kidney Centers. The funders had no role in study design, data collection, analysis, reporting, or the decision to submit for publication. The authors declare that they have no relevant financial interests. Received March 30, 2020. Evaluated by 3 external peer reviewers and a statistician, with editorial input from an Acting Editor-in-Chief (Editorial Board Member Wendy L. St. Peter, PharmD). Accepted in revised form September 26, 2020. The involvement of an Acting Editor-in-Chief to handle the peer-review and decision-making processes was to comply with AJKD's procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.
Funding Information:
This study was supported by NIH grants R01 DK103612 (NB) and R01 DK104730 (AA). Roche Diagnostics provided partial funding for the NT-proBNP and hsTnT assays. Funding for the CRIC Study was obtained under a cooperative agreement from National Institute of Diabetes and Digestive and Kidney Diseases ( U01DK060990 , U01DK060984 , U01DK061022 , U01DK061021 , U01DK061028 , U01DK060980 , U01DK060963 , and U01DK060902 ). In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award National Institutes of Health (NIH)/ National Center for Advancing Translational Sciences (NCATS) UL1TR000003 , Johns Hopkins University UL1 TR-000424 , University of Maryland General Clinical Research Center M01 RR-16500 , Clinical and Translational Science Collaborative of Cleveland , UL1TR000439 from the NCATS component of NIH and NIH roadmap for Medical Research, Michigan Institute for Clinical and Health Research UL1TR000433 , University of Illinois at Chicago Clinical and Translational Science Award UL1RR029879 , Tulane Center of Biomedical Research Excellence for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036 , Kaiser Permanente NIH/ National Center for Research Resources UCSF-CTSI UL1 RR-024131 , and an unrestricted fund from the Northwest Kidney Centers . The funders had no role in study design, data collection, analysis, reporting, or the decision to submit for publication.
Publisher Copyright:
© 2020 National Kidney Foundation, Inc.
PY - 2021/6
Y1 - 2021/6
N2 - Rationale & Objective: Circulating cardiac biomarkers may signal potential mechanistic pathways involved in heart failure (HF) and atrial fibrillation (AF). Single measures of circulating cardiac biomarkers are strongly associated with incident HF and AF in chronic kidney disease (CKD). We tested the associations of longitudinal changes in the N-terminal fragment of the prohormone brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hsTnT), galectin-3, growth differentiation factor 15 (GDF-15), and soluble ST-2 (sST-2) with incident HF and AF in patients with CKD. Study Design: Observational, case-cohort study design. Setting & Participants: Adults with CKD enrolled in the Chronic Renal Insufficiency Cohort study. Exposures: Biomarkers were measured at baseline and 2 years later among those without kidney failure. We created 3 categories of absolute change in each biomarker: the lowest quartile, the middle 2 quartiles, and the top quartile. Outcomes: The primary outcomes were incident HF and AF. Analytical Approach: Cox proportional hazards regression models were used to test the associations of the change categories of each cardiac biomarker with each outcome (with the middle 2 quartiles of change as the referent group), adjusting for potential confounders and baseline concentrations of each biomarker. Results: The incident HF analysis included 789 participants (which included 138 incident HF cases), and the incident AF analysis included 774 participants (123 incident AF cases). In multivariable models, the top quartile of NT-proBNP change (>232 pg/mL over 2 years) was associated with increased risk of incident HF (HR, 1.79 [95% CI, 1.06-3.04]) and AF (HR, 2.32 [95% CI, 1.37-3.93]) compared with the referent group. Participants in the top quartile of sST2 change (>3.37 ng/mL over 2 years) had significantly greater risk of incident HF (HR, 1.89 [95% CI, 1.13-3.16]), whereas those in the bottom quartile (≤−3.78 ng/mL over 2 years) had greater risk of incident AF (HR, 2.43 [95% CI, 1.39-4.22]) compared with the 2 middle quartiles. There was no association of changes in hsTnT, galectin-3, or GDF-15 with incident HF or AF. Limitations: Observational study. Conclusions: In CKD, increases in NT-proBNP were significantly associated with greater risk of incident HF and AF, and increases in sST2 were associated with HF. Further studies should investigate whether these markers of subclinical cardiovascular disease can be modified to reduce the risk of cardiovascular disease in CKD.
AB - Rationale & Objective: Circulating cardiac biomarkers may signal potential mechanistic pathways involved in heart failure (HF) and atrial fibrillation (AF). Single measures of circulating cardiac biomarkers are strongly associated with incident HF and AF in chronic kidney disease (CKD). We tested the associations of longitudinal changes in the N-terminal fragment of the prohormone brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hsTnT), galectin-3, growth differentiation factor 15 (GDF-15), and soluble ST-2 (sST-2) with incident HF and AF in patients with CKD. Study Design: Observational, case-cohort study design. Setting & Participants: Adults with CKD enrolled in the Chronic Renal Insufficiency Cohort study. Exposures: Biomarkers were measured at baseline and 2 years later among those without kidney failure. We created 3 categories of absolute change in each biomarker: the lowest quartile, the middle 2 quartiles, and the top quartile. Outcomes: The primary outcomes were incident HF and AF. Analytical Approach: Cox proportional hazards regression models were used to test the associations of the change categories of each cardiac biomarker with each outcome (with the middle 2 quartiles of change as the referent group), adjusting for potential confounders and baseline concentrations of each biomarker. Results: The incident HF analysis included 789 participants (which included 138 incident HF cases), and the incident AF analysis included 774 participants (123 incident AF cases). In multivariable models, the top quartile of NT-proBNP change (>232 pg/mL over 2 years) was associated with increased risk of incident HF (HR, 1.79 [95% CI, 1.06-3.04]) and AF (HR, 2.32 [95% CI, 1.37-3.93]) compared with the referent group. Participants in the top quartile of sST2 change (>3.37 ng/mL over 2 years) had significantly greater risk of incident HF (HR, 1.89 [95% CI, 1.13-3.16]), whereas those in the bottom quartile (≤−3.78 ng/mL over 2 years) had greater risk of incident AF (HR, 2.43 [95% CI, 1.39-4.22]) compared with the 2 middle quartiles. There was no association of changes in hsTnT, galectin-3, or GDF-15 with incident HF or AF. Limitations: Observational study. Conclusions: In CKD, increases in NT-proBNP were significantly associated with greater risk of incident HF and AF, and increases in sST2 were associated with HF. Further studies should investigate whether these markers of subclinical cardiovascular disease can be modified to reduce the risk of cardiovascular disease in CKD.
KW - Chronic kidney disease (CKD)
KW - N-terminal fragment of the prohormone brain natriuretic peptide (NT-proBNP)
KW - atrial fibrillation (AF)
KW - biomarker trajectory
KW - cardiac biomarkers
KW - galectin-3
KW - growth differentiation factor 15 (GDF-15)
KW - heart failure (HF)
KW - high-sensitivity troponin T (hsTnT)
KW - soluble ST-2 (sST-2)
UR - http://www.scopus.com/inward/record.url?scp=85101097009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101097009&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2020.09.021
DO - 10.1053/j.ajkd.2020.09.021
M3 - Article
C2 - 33309861
AN - SCOPUS:85101097009
SN - 0272-6386
VL - 77
SP - 907
EP - 919
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 6
ER -